NASDAQ:TNFA - Nasdaq - US62856X2018 - Common Stock - Currency: USD
0.479
-0.01 (-2.62%)
The current stock price of TNFA is 0.479 USD. In the past month the price decreased by -58.35%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.58 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. The company is headquartered in Baltimore, Maryland and currently employs 9 full-time employees. The company went IPO on 2008-07-24. The company is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets: MYMD-1 and Supera-CBD. MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. Supera-CBD is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the growing CBD market, which includes both Food and Drug Administration (FDA) approved drugs and CBD products not currently regulated as drugs.
TNF PHARMACEUTICALS INC
855 N. Wolfe Street, Suite 601
Baltimore MARYLAND US
Employees: 9
Company Website: https://tnfpharma.com/
Investor Relations: https://ir.mymd.com/
Phone: 18568488698
The current stock price of TNFA is 0.479 USD. The price decreased by -2.62% in the last trading session.
The exchange symbol of TNF PHARMACEUTICALS INC is TNFA and it is listed on the Nasdaq exchange.
TNFA stock is listed on the Nasdaq exchange.
TNF PHARMACEUTICALS INC (TNFA) has a market capitalization of 1.32M USD. This makes TNFA a Nano Cap stock.
TNF PHARMACEUTICALS INC (TNFA) currently has 9 employees.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TNFA does not pay a dividend.
TNF PHARMACEUTICALS INC (TNFA) will report earnings on 2024-11-12, after the market close.
The outstanding short interest for TNF PHARMACEUTICALS INC (TNFA) is 15.14% of its float. Check the ownership tab for more information on the TNFA short interest.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to TNFA. The Buy consensus is the average rating of analysts ratings from 7 analysts.